Science in Society Archive

Unravelling AIDS

What is the real extent of the AIDS epidemic? Why does AIDS attract so much controversy? Do conventional anti HIV drugs do more harm than good? Are there safe and effective treatments that can be made widely available at affordable costs?

This special mini-series is part of an in-depth report, Unravelling AIDS

Can Exercise Help Prevent & Treat AIDS?

Dr. Veljko Velkovic presents evidence on how exercise may help treat and prevent AIDS, and if so, the simplest, most widely available and affordable natural 'vaccine' is being ignored.

The most effective way to control the HIV/AIDS pandemic would be the development of a safe and effective HIV vaccine. Unfortunately, despite enormous scientific and financial resources being deployed worldwide over the past 15 years, no vaccine candidate is on the immediate horizon [1,2] (but see "Pink panacea, an AIDS vaccine?" this series). There are strong indications, besides, that the AIDS vaccines currently tested in humans are not only ineffective but also harmful [3-5]. In addition, current medical therapy of HIV disease is extremely toxic, with multiple side effects and drug interactions (see "AIDS & HIV?" this series). It is also very expensive, and carries risks of developing drug-resistant HIV strains.

It is clearly desirable to pursue other less toxic, inexpensive, non-drug approaches in order to slow the spread of HIV infection and to decrease the burden of HIV infection and treatment.

The answer may come from certain antibodies that appear to be directly involved in controlling HIV disease progression [6,7]. These antibodies have specific affinity, or cross reactivity, to the HIV-1 envelope protein (gp120 surface antigen, residues 280-302, designated peptide NTM); but may be naturally occurring auto-antibodies (antibodies generated against the individual's own antigens) against a small protein molecule that acts to dilate the blood vessels in the intestine, the vasoactive intestinal peptide (VIP) [8,9].

It so happens that aerobic exercise training stimulates the formation of these anti-VIP/NTM antibodies [10] in both normal and HIV-positive individuals, and perhaps both could benefit from such exercise [9].

Increased levels of anti-VIP/NTM antibodies induced by exercise may have two beneficial effects. First, in HIV-negative individuals, the anti-VIP/NTM antibodies could bind HIV particles in circulation and prevent them from reaching their target cell, thereby, reducing the risk of infection with HIV and decrease the transmission of the disease. Second, in HIV-positive individuals, increased levels of anti-VIP/NTM could slow HIV disease progression and reconstitute the damaged immune system.

Aerobic exercise may be an important, inexpensive, non-toxic, widely available front line defence and therapy against HIV/AIDS. By acting as an immune stimulant (for both HIV positive and HIV negative individuals), it creates a type of "natural vaccine" that, if widely adopted, could contribute to a worldwide slow-down of the AIDS pandemic.

HIV and AIDS disease
The first step in HIV infection involves the gp 120 on the outer envelope of the virus binding to receptors on the cell surface of the host, allowing the HIV virus to enter the cell. The central portion of the gp120 molecule has an immunoglobulin-like structure, which facilitates participation in the immune network. Therefore, immediately after infection, HIV tries to produce a fit to the host idiotype (individual type) by producing thousands of variants of gp120. This process of adaptation usually takes years, and during this time, the host immune system is more or less able to control the HIV disease.

In some HIV-infected persons, this period is short, and in others it can be quite long, giving rise to the designations "slow" and "fast" disease progression. After this latent period, a separate fraction of viruses will be established whose gp120 carries the host idiotype [11-13]. This population of HIV becomes accepted by the host immune system as 'self' and therefore protected from the host's immune attack. Even worse, these gp120 molecules will be included in regulation of the immune network, destabilizing its vital components and accelerating progression of disease [14]. In this way, HIV may escape from the latent period and progressively destroy the immune system of the infected person.

The gp120 protein represents the key component of all AIDS vaccine candidates that are currently in clinical trials. These vaccines may have an important flaw in that they produce antibodies that neutralize only the HIV variants, which carry vaccine-like gp120. As the variants of gp120 are produced by the HIV infection, the vaccine antibodies may have the effect of disarming the immune system's antiviral response and thus, increasing the likelihood of rapid disease progression [1,4,5]. This phenomenon has been seen in gp120 vaccine volunteers who later became infected with HIV [15,16], and would certainly reduce the utility of an HIV vaccine in AIDS prevention.

Useful auto-antibodies in HIV disease
If an Achilles' heel exists in HIV, it might be in the central portion of gp120 (residues 280-302, RSANFTDNACTIIVQLNESVEIN, designated as peptide NTM [6]). (The letters stand for different amino acids: R=Arginine, S=Serine, A=Alanine, N=Asparagine, F=Phenylalanin, T=Threonine, D=Aspartic acid, C=Cystine, I=Isoleucine V=Valine, Q=Glutamine, L=Leucine, E=Glutamic acid) This portion of the molecule is highly conserved in all known HIV variants and appears to be crucial for viral infectivity. In fact, researchers have demonstrated that minimal changes in this sensitive peptide region will completely abolish HIV infectivity. Unfortunately, this part of gp120 is not immunogenic in humans [17] because the immune system treats this part of gp120 as 'self', possibly due to peptide 's similarity to several human proteins [18]. However, an antibody, found in both HIV positive and HIV negative individuals, seems to have reactivity to this region of the gp120 molecule.

A computer-assisted search of the Swiss-Prot database reveals vasoactive intestinal peptide (VIP) as the best match to NTM among currently analyzed human proteins [8,9]. The antibodies reacting to NTM may therefore be auto-antibodies against VIP.

VIP is a small naturally occurring peptide, which plays several important roles in the human body as a vasodilatator (dilates blood vessels), neurotransmitter, and modulator of the immune system.

VIP stimulates natural killer (NK) cells in the immune system (among the first line of defence against infection) and also the production of cytokine, a hormone that influences the activity of other cells in the immune system. VIP therefore has a very important role in modulating the immune system.

The HIV protein gp120 is sufficiently similar to VIP to serve as a molecular mimic and interfere with its function. The main consequence of this mimicry is to undermine the NK cells, making them dysfunctional, which is common in HIV-infected subjects. As Peruzzi and co-workers demonstrated, gp120 inhibits the ability of NK cells to kill infected cells, and this inhibition affects also the production of the pro-inflammatory cytokine IFN-gamma [19], which enlists the help of other cells in the immune system to fight the infection.

Thus, increase in circulating VIP can counteract the effects of the HIV gp120, by overcoming the latter's inhibition of NK cells, and by stimulating the production of VIP auto-antibodies which can also bind gp120 and prevent it from binding to NK cells.

Finally, both VIP and the peptide NTM has been previously identified as possessing sequence characteristics responsible for the interaction between HIV and the CD4 receptor [20], which represents the first step in process of infection.

It has also been demonstrated that sera from HIV-negative asthma patients contains high levels of natural anti-VIP antibodies with peptide NTM reactivity. A recent study on sera from 393 HIV- blood donors found that approximately 5% (21/393) contain significant levels of the anti-VIP/NTM antibodies, corresponding to two standard deviations above average.

For HIV+ individuals, the amount of anti-VIP/NTM antibodies available appears to strongly correlate with progression of HIV disease, suggesting that the immune system is attempting to overcome the infection. HIV patients in the first stage of illness (characterized by CD4 lymphocytes count greater than 500/ml), when the immune system is efficiently controlling HIV, have very low levels of anti-VIP/NTM reactive antibodies, similar to levels in normal HIV- people [21].

The level of these antibodies significantly increases in disease stages corresponding to CD4 values between 200 and 500/ml. Below that CD4 level (less than 200/ml), however, the amount of anti-VIP/NTM antibody sharply decreases. In the terminal stages of AIDS disease, NTM-reactive antibodies in sera of HIV+ patients appear to be significantly decreased.

Neurath and co-workers have also reported differences in the spectrum of antibodies against HIV gp120 in two groups of HIV-infected individuals, those who remained healthy for at least 10 years, and those who developed AIDS within 5 years of the onset of infection [6]. They found antibodies recognizing the peptide 280-306 of HIV-1 gp 120 (overlapping NTM) significantly more prevalent in asymptomatic carriers than in AIDS patients. Thus, the absence or disappearance of these antibodies may be a possible factor contributing to the development of AIDS [6].

Exercise as a natural source of VIP/NTM reactive antibodies
A unique method to produce high titers of VIP/NTM reactive antibodies may be available to both HIV- and HIV+ individuals. An article by Paul and Said in 1988 [10] showed that auto-antibodies to VIP were present in plasma from 29.6% of healthy (HIV-) human subjects who habitually performed aerobic muscular exercise, compared to 2.3% of healthy subjects who did not. The exercise involves running, cycling, swimming, aerobic dancing, and/or weight training, three or more workouts per week for a year or more prior to the study. The antigenic stimulus for the formation of these auto-antibodies could not be identified from their data. However, acute exercise has been shown to be associated with a brisk increase in plasma levels of VIP [22,23]. It is possible therefore that the antibodies may have been produced in response to increased VIP levels during exercise.

Effect of aerobic exercise training on HIV-positive individuals
Several studies on aerobic exercise training in HIV-positive individuals have demonstrated that it is safe, effective, and has a number of beneficial outcomes [24-38]. The aerobic exercise fitness improvements include a 10-25% improvement in lactic acidosis threshold (a sign of fatigue) and 5-10% increase in maximal oxygen uptake depending on the exercise training intensity. In addition, despite concerns about the stress of aerobic exercise on already damaged immune systems (specifically, increases in infections, morbidity, or mortality), there have been no documented adverse effects of aerobic exercise training in HIV-positive patients at either moderate or heavy exercise training levels [25]. The available literature clearly supports the idea that aerobic exercise is well tolerated by HIV-positive individuals.

With regards to immunologic improvement with aerobic exercise training, CD4 counts or viral loads may or may not improve during the exercise intervention in exercise (see below), although skin test reactivity to Candida antigen has been shown to improve with moderate exercise. The quality of life outcomes, however, were found to have improved significantly with aerobic exercise training relative to a non-exercising control group.

There are indications that exercise can stabilize CD4 cell count in HIV-infected individuals. Studies showed that people with CD4 cells between 200 - 500 /ml seemed to benefit the most from an exercise program. A pilot study performed by Olson and co-workers found that the mean change in CD4 percentage over the 24 months interval for weight lifters was -3.1% compared with -5.9% for runners [26]. According to these researchers, among HIV infected patients motivated to and capable of regular strenuous exercise, weight training may offer a salutary benefit superior to intense running. The same authors have also reported a case of a long-term survivor (12 years HIV+) of a tri-athlete with a rigorous daily exercise regimen demonstrating very low viral burden as reflected in non-detectable HIV RNA quantitative PCR and increase in CD4 during 6 years from 3 to 50 /ml (usual CD4 cell count is > 800 /ml) [27]. There was a report that exercise facilitated a return of the CD4 cell count to more normal levels [28].

In a large study involving 415 individuals (156 HIV positive and 259 HIV negative) Mustafa and co-workers demonstrated that exercising 3 - 4 times/week had a more protective effect than daily exercise [29]. Exercise in the HIV positive group covered by this study showed an increase in CD4 count during a year by a factor of 7%. It should be noted that some authors have reported moderate training can be sustained without any large change in CD4 cell count [30-32].

Exercise for the masses
Aerobic exercise training has been shown to be a promising, non-toxic, non-drug adjunct therapy to improve physical fitness, increase quality of life, and potentially improve the immune status (as indicated by reactivity to Candida skin test) of HIV-positive individuals. If aerobic exercise training can also be shown to increase the titer of anti-VIP/NTM antibodies in normal individuals (potential to decrease the risk of HIV transmission) and in HIV-positive individuals (potential to slow disease progression), it would strengthen its case to serve as a widely available and affordable intervention that is non-toxic and free of drug interactions. It would be applicable worldwide, in both developed and developing countries.

Article first published 06/04/04


  1. Veljkovic V, Metlaš R, Kohler H, Urnovitz HB, Prljic J, Veljkovic N, Johnson E, Muller S. AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy. Vaccine 19, 1855-1862 (2001)
  2. Kohler H, Muller S, Veljkovic V. No hope for an AIDS vaccine soon. AIDScience 2002, 2, 5-6.
  3. Veljkovic V, Johnson E and Metlaš R. Molecular basis of the inefficacy and possible harmful effects of AIDS vaccine candidates based on HIV-1 envelope glycoprotein gp120. Vaccine 15, 1997, 437-8.
  4. Veljkovic V, Muller S and Kohler H. Does VaxGen hide the breakthrough infections. Lancet 2003, 361, 1743-4.
  5. Veljkovic V, Muller S and Kohler H. AIDSVAX results: an important open question. Vaccine 2003, 21, 3528-9.
  6. Neurath AR, Strick N and Taylor P. Search for epitope-specific antibody responses to the HIV-1 envelope glycoprotein signifying resistance to disease development. AIDS Res Human Retrovir 1990, 6,1183-92.
  7. Veljkovic V, Metlaš R, Jevtovic DJ ad Stringer W. The role of passive immunization in hiv-positive patients: a case report. Chest 2001, 120, 662-6.
  8. Veljkovic V, Metlaš R, Raspopovic J and Pongor S. Spectral and sequence similarity between VIP and the second conserved region of HIV envelope glycoprotein gp120: possible consequences on prevention and therapy of AIDS. Biochem Biophys Res Commun 1992, 189, 705-10.
  9. Veljkovic V, Metlaš R, Vojvodic D, Cavor LJ, Pejinovic N, Dujic A, Zakhariev S, Guarnaccia C and Pongor S. Natural autoantibodies cross-react with a peptide derived from the second conserved region of HIV-1 envelope glycoprotein gp120., Biochem Biophys Res Commun 1993, 196, 1019-24.
  10. Paul S and Said SI. Human autoantibody to vasoactive intestinal peptide: Increased incidence in muscular exercise. Life Sciences, 1988, 43, 1079-84.
  11. Veljkovic V, Metlaš R, HIV and idiotypic T-cell regulation: another view. Immunol Today1992, 15, 39-40.
  12. Metlaš R, Trajkovic D, Srdic T, Veljkovic V and Colombatti A. Human immunodeficency virus V3 peptide-reactive antibodies are present in normal HIV-negative sera. AIDS Res Hum Retrovir 1999, 15, 671-7.
  13. Metlaš R, Trajkovic D, Srdic T, Veljkovic V smf Colombatti A. Anti-V3 and anti-IgG antibodies of healthy individuals share complementarity structures. J Acquir Immune Defic Synd 1999, 21, 266-70.
  14. Metlaš R and Veljkovic V. Does HIV-1 gp120 manipulate human immune network. Vaccine1995, 13, 355-9.
  15. McElrath M, Corey L, Greenberg P.D, Matthews D.C, Rowen L, Mullins J.I. Human Immunodeficiency Virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. Proc Natl Acad Sci USA 1996, 93, 3972-6.
  16. LocherCP, Grant RM, Collisson EA, Reyes-Teran G, Elbeik T, Kahn JO and Levy JA. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination. AIDS Res Hum Retrovir 1999, 71, 1685-9.
  17. Bradac JA, Mathieson BJ. An epitope map of immunity to HIVHIV-1: a roadmap for vaccine development. Div of AIDS, NIAID, NIH 1991
  18. Veljkovic V, Johnson E and Metlaš R. Analogy of HIV-1 to oncogenic viruses: possible implications for the pathogenesis of AIDS. Cancer J1995, 8, 308-12.
  19. Peruzzi M, Azzari C, Rossi ME, De Martino M, Vierucci A. "Inhibition of natural killer cell cytotoxicity and interferon gamma production by the envelope protein of HIV and prevention by vasoactive intestinal peptide". AIDS Res Human Retrovir 2000. 16: 1067-1074.
  20. Veljkovic V., Metlaš R., Identification of nanopeptide from HTLV3, LAV and ARV-2 envelope gp120 determining binding to T4 cell surface protein. Cancer Biochem. Biophys 1988, 10, 191-206.
  21. Veljkovic V et al (in preparation)
  22. Woie L, Kaada B, Opstad PK. Increase in plasma vasoactive intesinal polypeptide (VIP) in muscular exercise in humans. Gen Pharmacol 1986, 17, 321-9.
  23. MacLaren DP. Human gastrin and vasoactive intestinal polypeptide responses to endurance running in relation to training status and fluid ingested. Clin Sci 1995, 89, 137-46.
  24. Johnson J, Anders G, Blanton H et al. Exercise dysfunction in patients seropositive for the human immunodeficiency virus-1. Am Rev Respir Dis 1990, 141, 618-25.
  25. Stringer WW. HIV and aerobic exercise: Current Recommendations. Sports Medicine 1999, 28, 387-97.
  26. Olson PE, Wallace MR, Carl M. CD4+ correlates of weight training in HIV-seropositive outpatients. Natl Conf Hum Retroviruses Relat Inf (2nd) 1995, 155.
  27. Olson PE, Elrick H, Cohan GR, Wallace MR. Non-detectable quantitative HIV PCR in a long-term survivor triathlete. Int Conf AIDS 1996; 11: 140 (abst. no. We.C.3472).
  28. LaPerriere A, Klimas N, Fletcher MA, Perry A, Ironson G, Perna F, Schneiderman N. Change in CD4+ cell enumeration following aerobic exercise training in HIV-1 disease: possible mechanisms and practical applications. Int J Sports Med 1997, 18 Suppl. 1: S56-S63.
  29. Mustafa T, Sy FS, Macera CA, Thompson SJ, Jackson KL, Selassie A, Dean LL. Association between exercise and HIV disease progression in a cohort of homosexual man. Ann Episemiol 1999, 9, 127-39.
  30. Smith BA, Neidig J, Nickel J, Frid D, Para M, Fass R. Effects of aerobic and resistive exercise on symptoms, immune status, and viral load in HIV+ men and women. Int. Conf. AIDS 1996; 11: 23 (abst. no. Mo.B.304).
  31. Smith BA, Neidig J, Nickel J, Frid D, Para M and Fass R. Effects of aerobic and resistive exercise training on body composition, immune markers, and viral load in HIV+ adults with CD4+ counts 200-499/mm3. Int. Conf. AIDS 1998, 12: 839 (abst. no. 42328).
  32. Shephard RJ. Exercise, immune function and HIV infection. J Sport Med Phys Fitness 1998, 38, 101-7.
  33. MacArthur RD, Levine SD and Berk TJ. Supervised exercise training improves cardiopulmonary fitness in HIV-infected persons. Med Sci Sports Exerc 1993, 25, 684-97.
  34. Perna FM, LaPerriere A, Klimas NG et al. Cardiopulmonary and CD4 changes inresponse to exercise training in early symptomatic HIV infection. Med Sci Sports Exerc 1999, 31, 973-82.
  35. Pothoff G, Wasserman K and Ostmann H. Impairment of exercise capacity in various groups of HIV-infected patients. Respiration 1994, 61, 80-5.
  36. Rigsby LW, Dishman RK, Jackson AW et al. Effects of exercise training on men seropositive for the human immunodeficiency virus-1. Med Sci. Sports Exerc 1992, 24, 6-14.
  37. Stringer WW, Berezovskaya M, O'Brien WA et al. The effect of exercise training on aerobic fitness, immune indices, and quality of life in HIV+ patients. Med Sci. Sports Exerc 1998, 30, 11-17.
  38. Terry L, Sprinz E, Ribeiro JP. Moderate and high intensity exercise training in HIV-1 seropositive individuals: a randomized trail. Int J Sports Med 1999, 20, 142-8.

Got something to say about this page? Comment

Comment on this article

Comments may be published. All comments are moderated. Name and email details are required.

Email address:
Your comments:
Anti spam question:
How many legs on a tripod?